Skip to content

Price / book at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
2.8×+2.2×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.1×+1.3×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
3.1×-0.4×
Precigen logo
PrecigenPGEN
67.7×
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
15.4×+2.4×
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
20.8×+19.4×

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.86B+468%

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's price / book?
Palvella Therapeutics (PVLA) reported price / book of 7.7× in Q1 2026.
How has Palvella Therapeutics's price / book changed year-over-year?
Palvella Therapeutics's price / book increased by 35.9% year-over-year, from 5.7× to 7.7×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.